[ad_1]
The brand of pharmaceutical firm Novo Nordisk is displayed in entrance of its places of work in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025.
Tom Little | Reuters
The U.S. Meals and Drug Administration on Monday permitted the first-ever GLP-1 tablet for weight problems from Wegovy maker Novo Nordisk, a landmark choice that well being consultants say may open up remedy entry to extra sufferers.
Novo Nordisk stated it expects to launch the tablet in early 2026. The Danish drugmaker stated the beginning dose of 1.5 milligrams shall be out there beginning in early January in pharmacies and by way of choose telehealth suppliers for $149 monthly.
Novo Nordisk didn’t say how a lot greater doses of the drug would price, however stated further data on protection and financial savings choices for eligible sufferers shall be out there at the moment as properly.
Shares of Novo Nordisk gained roughly 9% in prolonged buying and selling Monday.
The approval offers Novo Nordisk a head begin over chief rival Eli Lilly, which is at the moment the dominant participant out there and is racing to launch its personal weight problems tablet. Tablets are the following battleground for the 2 drugmakers, which established the booming GLP-1 area that some analysts say may very well be value roughly $100 billion by the 2030s.
Wall Road thinks there’s loads of room for drugs out there, with Goldman Sachs analyst saying in August that drugs may seize a 24% share — or round $22 billion — of the 2030 world weight reduction drug market.
“What we have discovered by years of analysis is that having an oral possibility actually type of opens up, prompts and motivates totally different segments to hunt remedy,” Dave Moore, Novo Nordisk’s government vice chairman of U.S. operations, informed CNBC forward of the approval. “To have that dialog with their physician to see if that is one thing that is perhaps proper for them.”
“That is what we’re enthusiastic about — to have the ability to give folks an possibility and ensure we have now entry and ease of entry like we have now been doing with our injections,” he continued.
The FDA’s approval additionally clears the tablet to be used to cut back the danger of main cardiovascular occasions, comparable to demise, coronary heart assault or stroke, in adults with weight problems and established heart problems, in line with Novo Nordisk. That is in step with the approval label of the corporate’s blockbuster weight reduction drug Wegovy, which shares the identical energetic ingredient, semaglutide.
The approval is predicated on a section three trial that adopted greater than 300 adults with weight problems however not diabetes.
In that examine, a 25-milligram dose of Novo Nordisk’s oral semaglutide helped sufferers lose as much as 16.6% of their weight on common after 64 weeks, in line with outcomes from the trial offered at a medical convention in 2024. That weight reduction was 13.6% when the corporate analyzed all sufferers no matter whether or not they stopped the drug.
The tablet seems to be barely more practical than an experimental oral drug from Eli Lilly, which remains to be ready for FDA approval.
However in contrast to Novo Nordisk’s tablet, Eli Lilly’s remedy just isn’t a peptide remedy. Meaning it’s absorbed extra simply by the physique and doesn’t require dietary restrictions. Individuals who take Novo Nordisk’s tablet have to attend half-hour earlier than consuming or consuming every day.
Moore stated the costs of the tablet get prices nearer to what some persons are paying for unapproved, compounded variations of branded GLP-1s, a few of that are nonetheless being illegally mass marketed and bought within the U.S.
Sufferers flocked to the cheaper copycats when Ozempic and Wegovy have been briefly provide during the last two years attributable to skyrocketing demand, or in the event that they did not have insurance coverage protection for the pricey remedies. Throughout FDA-declared shortages, pharmacists can legally make compounded variations of brand-name medicines. However the company earlier this yr decided that the scarcity of semaglutide is over, barring the apply normally.
“It continues to be alarming and disturbing for us,” Moore informed CNBC, referring to illegitimate components which are imported into the U.S. illegally and utilized by some compounding pharmacies to create copycat variations of GLP-1s.
That is breaking information. Please refresh for updates.
[ad_2]
